ReviewInternational journal of clinical pharmacy2022
Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review.
Review in International journal of clinical pharmacy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Anticoagulation approaches in hemodialysis: a systematic review of efficacy, safety, and literature gap.International urology and nephrology · 2026Pooled it
- Systematic review and meta-analysis of AI accuracy in warfarin dose prediction across ethnic groups.European journal of clinical pharmacology · 2026Pooled it
- Evaluation of large language model responses to patient questions on oral anticoagulant therapy: a comparative expert assessment.Exploratory research in clinical and social pharmacy · 2026Article
- Fixed dose versus 3-day loading dose warfarin initiation in atrial fibrillation: effects on INR stabilization and time in the therapeutic range.International journal of clinical pharmacy · 2026Article
- Health Equity Perspective on Data-Driven Treatment Decisions in Cardiovascular Care: Risk Assessments Versus Individualized Treatment Rules.Journal of the American Heart Association · 2026Observational
- Clinical, genetic, and nutritional determinants of INR: role of plasma warfarin and hydroxylated metabolite levels in anticoagulated Mexican patients.Journal of thrombosis and thrombolysis · 2026Article
- Knowledge, Attitude, and Practice Toward Long-Term Anticoagulation in Patients with Venous Thromboembolism: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Does direct oral anticoagulant lead-in dosing following initial parenteral therapy affect clinical outcomes in acute venous thromboembolism?: A retrospective cohort study.International journal of clinical pharmacy · 2025Article
- Terahertz Spectroscopy and Density Functional Theory for Non-Destructive Analysis of Anticoagulant Warfarin.Molecules (Basel, Switzerland) · 2025Article
- Analysis of Personalized Cardiovascular Drug Therapy: From Monitoring Technologies to Data Integration and Future Perspectives.Biosensors · 2025Review
- Poor clinical outcomes associated to multimorbidity, frailty and malnutrition in patients with atrial fibrillation.The journal of nutrition, health & aging · 2025Observational
- Pharmacogenomics revolutionizing cardiovascular therapeutics: A narrative review.Health science reports · 2024Article
- Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial).Clinical and translational science · 2024Article
- Optimal Strategies to Select Warfarin Dose for Thai Patients with Atrial Fibrillation.Journal of clinical medicine · 2024Article
- Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.Pharmacogenomics · 2023Observational
- Use of Warfarin in Oral Anticoagulation Therapy: Challenges and EmpoderACO Strategy for Promoting Patient Empowerment in Self-Care.Arquivos brasileiros de cardiologia · 2023Article
- Evaluation of supervised machine learning algorithms in predicting the poor anticoagulation control and stable weekly doses of warfarin.International journal of clinical pharmacy · 2023Article
- Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.Human genomics · 2022Article
- Assessing the Role of a Malonamide Linker in the Design of Potent Dual Inhibitors of Factor Xa and Cholinesterases.Molecules (Basel, Switzerland) · 2022Article
- Derivation and Validation of a Genotype- Guided Warfarin Dosing Model in a Mixed Arab Population.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Background For decades, vitamin K antagonists and specifically warfarin, have been the sole agents used orally to manage thromboembolic conditions, including stroke and venous thromboembolism (VTE). Several factors lead to warfarin dose variability, including genetic and non-genetic factors which made warfarin management challenging especially at the initiation phase. To overcome the challenges with warfarin dosing at initiation, strategies other than conventional or fixed dosing were introduced and explored. Aim In this narrative review, we aim to discuss and critique the different dosing strategies for warfarin at initiation with more focus on genotype-guided warfarin dosing and the most recent supporting evidence for and against its use. Method Medline database was searched from 1965 to July 2021. Articles addressing different warfarin dosing methods were screened for inclusion. Results A number of methods exist for warfarin initiation. Studies comparing different dosing methods for initiation yielded conflicting outcomes due to differences in study design, population studied, comparator, and outcomes measured. Conclusions Looking at the big picture, the use of genetic dosing for warfarin initiation can lead to better outcomes. Whether these better outcomes are clinically or economically beneficial remains controversial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.